Shah Nitin, Parikh Raunak, Casabona Giacomo, Kolhapure Shafi
PD Hinduja National Hospital, and #GSK; Mumbai, India; and $GSK, Wavre, Belgium. Correspondence to: Dr Raunak Parikh,GSK, Dr Annie Besant Rd, 400030 Mumbai, India.
Indian Pediatr. 2017 Dec 15;54(12):1041-1046. doi: 10.1007/s13312-017-1209-9.
A quadrivalent MMRV (measles-mumps-rubella-varicella) combination vaccine has recently been launched in India. This vaccine is highly immunogenic, with seroconversion rates against all antigens reaching 96.6-100% at 42 to 56 days after the second vaccine dose in unvaccinated children or in those previously vaccinated with MMR+/-V. Two doses efficacy, against all varicella is 94.1% and effectiveness reaches 91%. The most frequent solicited local adverse event after MMRV vaccine is redness, and fever is the most common solicited general symptom. Higher rates of fever and febrile convulsions compared to MMR+/-V have been reported when used as first dose but not when used as the second of a measles containing vaccine, irrespective of age of the second dose.
一种四价MMRV（麻疹-腮腺炎-风疹-水痘）联合疫苗最近在印度推出。这种疫苗具有高度免疫原性，在未接种疫苗的儿童或先前接种过MMR+/-V的儿童中，第二次接种疫苗后42至56天，针对所有抗原的血清转化率达到96.6-100%。两剂疫苗对所有水痘的效力为94.1%，有效性达到91%。MMRV疫苗接种后最常见的局部不良反应是发红，发热是最常见的全身症状。当用作第一剂时，与MMR+/-V相比，发热和热性惊厥的发生率更高，但用作含麻疹疫苗的第二剂时则不然，与第二剂的年龄无关。
